Identification of highly selective inhibitors of collagenase-1 from combinatorial libraries of diketopiperazines

Journal of Medicinal Chemistry

Volumn 42, Issue 8, 1999, Pages 1348-1357

  Szardenings, Anna Katrin ^a   Antonenko, Valery ^a   Campbell, David A ^a,b   DeFrancisco, Nuria ^a   Ida, Satoru ^a   Shi, Lihong ^a   Sharkov, Nikolai ^a   Tien, David ^a   Wang, Yongwen ^a   Navre, Marc ^a  

^a AFFYMAX RESEARCH INSTITUTE   (United States)

^b BAYER CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (4 METHOXYBENZYL) 6 (4 NITROBENZYL) 3 SULFANYLMETHYLHEXAHYDRO 2,5 PYRAZIEDIONE; COLLAGENASE INHIBITOR; GELATINASE INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; DRUG DESIGN; DRUG POTENCY; DRUG SELECTIVITY; DRUG SYNTHESIS; ENZYME INHIBITION; ENZYME SPECIFICITY; STRUCTURE ACTIVITY RELATION;

COLLAGENASES; DRUG DESIGN; MATRIX METALLOPROTEINASE 1; MATRIX METALLOPROTEINASE 9; PIPERAZINES; PROTEASE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0033594360     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm980475p     Document Type: Article

References (32)

1. Dolle, R. E. Discovery of enzyme inhibitors through combinatorial chemistry. Mol. Diversity 1997, 2, 223-236.
2. Szardenings, A. K.; Harris, D.; Lam, S.; Shi, L.; Tien, D.; Wang, Y.; Patel, D. V.; Navre, M.; Campbell, D. A. Rational Design and Combinatorial Evaluation of Enzyme Inhibitor Scaffolds: Identification of Novel Inhibitors of Matrix Metalloproteinases. J. Med. Chem. 1998, 41, 2194-2200.
3. Woessner, J. F., Jr. The family of matrix metalloproteinases. Ann. N.Y. Acad. Sci. 1994, 732, 11-21.
4. Nagase, H. In Zinc Metalloproteases in Health and Disease; Hooper, N. M., Ed.; Taylor & Francis: London, 1996; p 153-204.
5. Cawston, T. Matrix metalloproteinases and TIMPs: properties and implications for the rheumatic diseases. Mol. Med. Today 1998, 4, 130-137.
6. Bottomley, K. M.; Johnson, W. H.; Walter, D. S. Matrix metalloproteinase inhibitors in arthritis. J. Enzyme Inhib. 1998, 13, 79-101.
7. Yu, A. E.; Hewitt, R. E.; Connor, E. W.; Stetler-Stevenson, W. G. Matrix metalloproteinases: novel targets for directed cancer therapy. Drugs Aging 1997, 11, 229-244.
8. Wojtowicz-Praga, S.; Torri, J.; Johnson, M.; Steen, V.; Marshall, J.; Ness, E.; Dickson, R.; Sale, M.; Rasmussen, H. S.; Chiodo, T. A.; Hawkins, M. J. Phase I trial of marimastat, a novel matrix metalloproteinase inhibitor, administered orally to patients with advanced lung cancer. J. Clin. Oncol. 1998, 16, 2150-2156.
9. Davidson, A.; Drummond, A. H.; Galloway, W. A.; Whittaker, M. The inhibition of matrix metalloproteinase enzymes. Chem. Ind. (London) 1997, 258-261.
10. Denis, L. J.; Verweij, J. Matrix metalloproteinase inhibitors: present achievements and future prospects. Invest. New Drugs 1997, 15, 175-185.
11. Hagmann, W. K.; Larkk, M. W.; Becker, J. W. Inhibition of matrix metalloproteinases. Annu. Rep. Med. Chem. 1996, 31, 231-240.
12. Watson, S. A.; Tierney, G. Matrix metalloproteinase inhibitors: a review. BioDrugs 1998, 9, 325-335.
13. Levy, D.; Ezrin, A. Matrix metalloproteinase inhibitor drugs. Emerging Drugs 1997, 2, 205-230.
14. Zask, A.; Levin, J. I.; Killar, L. M.; Skotnicki, J. S. Inhibition of matrix metalloproteinases: structure based design. Curr. Pharm. Des. 1996, 2, 624-661.
15. Porter, J. R.; Beeley, N. R. A.; Boyce, B.; Mason, B. A.; Millican, A. W.; Millar, K. H.; Leonard, J.; Morphy, J. R.; O'Connell, J. P. Potent and selective inhibitors of gelatinase-A. 1. Hydroxamic acid derivatives. Bioorg. Med. Chem. Lett. 1994, 4, 2741-2746.
16. Sahoo, S. P.; Caldwell, C. G.; Chapman, K. T.; Durette, P. L.; Esser, C. K.; Kopka, I. r. E.; Polo, S. A.; Sperow, K. M.; Niedzwiecki, L. M.; Iizquierdo-Martin, M.; Chang, C. C.; Harrison, R. K.; Stein, R. L.; MacCoss, M.; Hagmann, W. K. Inhibition of matrix metalloproteinases by N-carboxyalkyl dipeptides: enhanced potency and selectivity with substituted P1′ homophenylalanines. Bioorg. Med. Chem. Lett. 1995, 5, 2441-2446.
17. Miller, A.; Askew, M.; Beckett, R. P.; Bellamy, C. L.; Bone, E. A.; Coates, R. E.; Davidson, A. H.; Drummond, A. H.; Huxley, P.; Martin, F. M.; Sariglou, L.; Thompson, A. J.; Van Dijk, S. E.; Whittaker, M. Inhibition of matrix metalloproteinases: an examination of the S1′ pocket. Bioorg. Med. Chem. Lett. 1997, 7, 193-198.
18. Freije, J. M. P.; Diez-Itza, I.; Balbin, M.; Sanchez, L. M.; Blasco, R.; Tolivia, J.; Lopez-Otin, C. Molecular cloning and expression of collagenase-3, a novel human matrix metalloproteinase produced by breast carcinomas. J. Biol. Chem. 1994, 269, 16766-73.
19. Mitchell, P. G.; Magna, H. A.; Reeves, L. M.; Lopresti-Morrow, L. L.; Yocum, S. A.; Rosner, P. J.; Geoghegan, K. F.; Hambor, J. E. Cloning, expression, and type II collagenolytic activity of matrix metalloproteinase-13 from human osteoarthritic cartilage. J. Clin. Invest. 1996, 97, 761-8.
20. Billinghurst, R. C.; Dahlberg, L.; Ionescu, M.; Reiner, A.; Bourne, R.; Rorabeck, C.; Mitchell, P.; Hambor, J.; Diekmann, O. Enhanced cleavage of type II collagen by collagenases in osteoarthritic articular cartilage. J. Clin. Invest. 1997, 99, 1534-1545.
21. Cawston, T. E. Metalloproteinase inhibitors and the prevention of connective tissue breakdown. Pharmacol. Ther. 1996, 70, 163-182.
22. Reboul, P.; Pelletier, J.-P.; Tardif, G.; Cloutier, J.-M.; Martel-Pelletier, J. The new collagenase, collagenase-3, is expressed and synthesized by human chondrocytes but not by synoviocytes. A role in osteoarthritis. J. Clin. Invest. 1996, 97, 2011-2019.
23. Shingleton, W. D.; Hodges, D. J.; Brick, P.; Cawston, T. E. Collagenase: a key enzyme in collagen turnover. Biochem. Cell Biol. 1996, 74, 759-775.
24. After the completion of this work, scientists from Roche published on a collagenase inhibitor, Ro 32-3555, that was selective over the gelatinases, but their publications gave no detailed insight into how this selectivity was achieved. Broadhurst, M. J.; Brown, P. A.; Lawton, G.; Ballantyne, N.; Borkakoti, N.; Bottomley, K. M. K.; Cooper, M. I.; Eatherton, A. J.; Kilford, I. R.; Malsher, P. J.; Nixon, J. S.; Lewis, E. J.; Sutton, B. M.; Johnson, W. H. Design and synthesis of the cartilage protective agent (CPA, Ro 32-3555). Bioorg. Med. Chem. Lett. 1997, 7, 2299-2302.
25. Morphy, J. R.; Millican, T. A.; Porter, J. R. Matrix metalloproteinase inhibitors: current status. Curr. Med. Chem. 1995, 2, 743-62.
26. Szardenings, A. K.; Burkoth, T. S.; Lu, H. H.; Tien, D. W.; Campbell, D. A. A simple procedure for the solid-phase synthesis of diketopiperazine and diketomorpholine derivatives. Tetrahedron 1997, 53, 6573-6593.
27. Borkakoti, N.; Winkler, F. K.; Williams, D. H.; D'Arcy, A.; Broadhurst, M. J.; Brown, P. A.; Johnson, W. H.; Murray, E. J. Structure of the catalytic domain of human fibroblast collagenase complexed with an inhibitor. Nat. Struct. Biol. 1994, 1, 106-110.
28. Stams, T.; Spurlino, J. C.; Smith, D. L.; Wahl, R. C.; Ho, T. F.; Qoronfleh, M. W.; Banks, T. M.; Rubin, B. Structure of human neutrophil collagenase reveals large S1′ specificity pocket. Nat. Struct. Biol. 1994, 1, 119-123.
29. Grams, F.; Reinemer, P.; Powers, J. C.; Kleine, T.; Pieper, M.; Tschesche, H.; Huber, R.; Bode, W. X-ray structures of human neutrophil collagenase complexed with peptide hydroxamate and peptide thiol inhibitors. Implications for substrate binding and rational drug design. Eur. J. Biochem. 1995, 228, 830-841.
30. Antonenko, V. A. Automation in Combinatorial Chemistry. In Combinatorial Chemistry and Combinatorial Technologies: Methods and Applications; Miertus, S., Fassina, G., Eds.; Marcel Dekker: New York, 1998 (in press).
31. Habeeb, A. F. S. A. Reaction of protein sulfhydryl groups with Ellman's reagent. In Methods Enzymology; Hirs, C. H. W., Ed.; Academic: New York, 1972; Vol. 25, pp 457-464.
32. Knight, C. G.; Willenbrock, F.; Murphy, G. A novel coumarin-labeled peptide for sensitive continuous assays of the matrix metalloproteinases. FEBS Lett. 1992, 296, 263-266.